SEC Form S-8 filed by Relay Therapeutics Inc.
As filed with the Securities and Exchange Commission on February 22, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Relay Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
47-3923475 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
399 Binney Street, 2nd Floor
Cambridge, MA 02139
(617) 370-8837
(Address of Principal Executive Offices)
Relay Therapeutics, Inc. 2020 Stock Option and Incentive Plan
Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan
(Full Title of the Plans)
Sanjiv K. Patel
President and Chief Executive Officer
Relay Therapeutics, Inc.
399 Binney Street, 2nd Floor
Cambridge, MA 02139
(617) 370-8837
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
William Collins, Esq.
Gabriela Morales-Rivera, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer |
|
☒ |
Accelerated filer |
☐ |
Non-accelerated filer |
|
☐ |
Smaller reporting company |
☐ |
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
This Registration Statement on Form S-8 is being filed for the purpose of registering (i) an additional 6,372,620 shares of common stock, par value $0.001 per share (“Common Stock”) of Relay Therapeutics, Inc. (the “Registrant”) to be issued under the Registrant’s 2020 Stock Option and Incentive Plan, as amended (the “2020 Plan”) and (ii) an additional 1,274,524 shares of Common Stock of the Registrant to be issued under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), for which Registration Statements on Form S-8 relating to the same employee benefit plans are effective.
Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on July 17, 2020 (File No. 333-239912), March 25, 2021 (File No. 333-254704), February 24, 2022 (File No. 333-262974), and February 23, 2023 (File No. 333-269959) related to the 2020 Plan and the 2020 ESPP are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
|
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
4.3 |
|
|
|
|
|
4.4 |
|
|
|
|
|
5.1* |
|
|
|
|
|
23.1* |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm |
|
|
|
23.2* |
|
|
|
|
|
24.1* |
|
|
|
|
|
99.1 |
|
|
|
|
|
99.2 |
|
|
|
|
|
107* |
|
* |
Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on the 22nd day of February, 2024.
|
|
|
RELAY THERAPEUTICS, INC. |
||
|
|
|
By: |
|
/s/ Sanjiv K. Patel |
|
|
Sanjiv K. Patel, M.D. |
|
|
President and Chief Executive Officer (Principal Executive Officer) |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Sanjiv K. Patel, M.D. and Brian Adams as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Sanjiv K. Patel |
|
President, Chief Executive Officer and Director |
|
February 22, 2024 |
Sanjiv K. Patel, M.D. |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Thomas Catinazzo |
|
Chief Financial Officer |
|
February 22, 2024 |
Thomas Catinazzo |
|
(Principal Accounting Officer and Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Alexis Borisy |
|
Director |
|
February 22, 2024 |
Alexis Borisy |
|
|
|
|
|
|
|
|
|
/s/ Linda A. Hill |
|
Director |
|
February 22, 2024 |
Linda A. Hill, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Douglas S. Ingram |
|
Director |
|
February 22, 2024 |
Douglas S. Ingram |
|
|
|
|
|
|
|
|
|
/s/ Sekar Kathiresan |
|
Director |
|
February 22, 2024 |
Sekar Kathiresan, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Mark Murcko |
|
Director |
|
February 22, 2024 |
Mark Murcko, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Jami Rubin |
|
Director |
|
February 22, 2024 |
Jami Rubin |
|
|
|
|
|
|
|
|
|
/s/ Laura Shawver |
|
Director |
|
February 22, 2024 |
Laura Shawver, Ph.D. |
|
|
|
|
|
|
|
|
|